These gaps stem from systemic barriers, including limited access to early detection, follow-up delays and inequities in ...

Based on data including more than 788 million patient visits from more than 15,000 ophthalmologists, thousands of eyes were ...

Tzield, a monoclonal antibody approved for stage 2 Type 1 diabetes, now seeks approval for stage 3 disease based on trial ...

However, ongoing studies, including perianal fistulizing disease trials and the REASON study evaluating transmural healing, will address some of these knowledge gaps in the future. For patients, the ...

An expert discusses how underutilization of combination lipid-lowering therapies stems from overly complex guidelines, primary care providers managing multiple chronic diseases simultaneously, cost ...

Researchers of the National Eye Institute found that the supplement—now known as the AREDS formula, containing vitamins C and ...

Bandyopadhyay and colleagues found that new T1D registrations were most likely to come from people under the age of 40, ...

Kenneth A. Beckman, M.D., doesn’t see insurers as standing in the way of patients getting treated with the “epi-on” approach ...

The new treatments Gilhooley referred to are calcitonin gene-related peptide (CGRP) inhibitors, a class that includes ...

In an interview conducted by Ophthalmology Times on behalf of Managed Healthcare Executive, Beckman listed some of the ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

Beckman said it is important to treat keratoconus with corneal collagen crosslinking early to prevent vision loss, although ...